SINONASAL UNDIFFERENTIATED CARCINOMA
Clinical trials for SINONASAL UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SINONASAL UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for SINONASAL UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Matched conditions: SINONASAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo treatment may spare head and neck cancer patients from disfiguring surgery
Disease control Recruiting nowThis study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can perform less extensive, function-preserving operations, reducing damage to swallowing, speech, and vision. The trial e…
Matched conditions: SINONASAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy plus chemo shows promise for rare sinus cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can shrink advanced sinonasal undifferentiated carcinoma (SNUC), a rare and aggressive sinus cancer. About 28 adults with newly diagnosed, locally advanced SNUC will recei…
Matched conditions: SINONASAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC